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ABSTRACT
Objective: This study was designed to conduct forced degradation and validation studies for the simultaneous estimation of metformin, sitagliptin, 
pioglitazone, and glimepiride.
Methods: Analytes were separated on an Agilent XDB-C18, 150 × 4.6 mm, 5 μm column using an isocratic elution mode having mobile phase 
composition of 20 mM potassium dihydrogen phosphate buffer (pH 4.0):acetonitrile (65:35% v/v). Analytes were detected at a wavelength of 225 nm. 
The optimized method was validated as per the ICH Q2 guidelines.
Results: The retention times of metformin, sitagliptin, pioglitazone, and glimepiride were 3.47, 4.83, 5.83, and 9.44 min, respectively. The linearity was 
25–100 μg/ml for metformin, 2.5–10 μg/ml for sitagliptin, 1–4 μg/ml for pioglitazone, and 0.75–3 μg/ml for glimepiride. The correlation coefficient 
for calibration curves was >0.99, and accuracy was between 98 and 102% for each analyte. Inter- and intra-day precisions were calculated <2% 
relative standard deviation for each analyte.
Conclusion: A significant degradation was observed in the presence of acidic, basic, neutral, oxidative, and photolytic stress conditions. The method 
is simple, precise, accurate, robust, and reproducible and was able to successfully separate and quantify metformin, sitagliptin, pioglitazone, and 
glimepiride in the presence of their degradation products.
Keywords: Metformin, Sitagliptin, Pioglitazone, Glimepiride, Stress testing, Degradation products, Stability-indicating method, Reversed-phase liquid 
chromatographic.
INTRODUCTION
Type 2 diabetes mellitus (T2DM) is the most prevalent metabolic disease 
worldwide. Inadequate management and control of hyperglycemia in 
patients with T2DM may lead to the risk of developing complications 
over the long term due to chronic and progressive nature of the 
disease arising from pathophysiology of beta-cell dysfunction, insulin 
resistance, and increased hepatic glucose output. Patients with T2DM 
often require a combination of therapeutic agents to achieve glycemic 
control over the long term [1-6].
Fixed-dose combination (FDC) therapies have been shown to improve 
adherence by reducing costs, pill burden, and the complexity of treatment 
regimen [8-10]. A treatment approach with a FDC that includes a 
combination of antidiabetic medications could be used to obtain 
adequate glycemic control in patients with type 2 diabetes. Fig. 1a-d 
represents the structures of metformin, sitagliptin, pioglitazone, and 
glimepiride, respectively [14-17]. A combined formulation consisting of 
metformin, sitagliptin, and pioglitazone or glimepiride in a single tablet 
would potentially offer increased patient convenience and subsequent 
potential for increased therapeutic compliance and can be studied for 
the treatment of adults with inadequately controlled T2DM to improve 
glycemic control. A clinical trial was conducted for the evaluation of 
sitagliptin in combination with metformin and sulfonylurea [13]. The 
aim of that clinical trial protocol was to determine the non-inferiority of 
the effectiveness of sitagliptin compared to a control group of patients 
treated with thiazolidinedione as add-on therapy, in low-income ethnic 
minority type 2 diabetic patients who are failing to maintain adequate 
control with maximal doses of metformin and a sulfonylurea agent.
Advantages of simultaneous stability studies are the identification of new 
degradation products, to understand mutual induction and/or inhibition of 
rates of degradation and to analyze the degradation products of both drugs. 
As per the literature survey, all the reported ultraviolet (UV) spectroscopic 
and high-performance liquid chromatographic (HPLC) assay methods 
were based on the estimation of metformin, sitagliptin, pioglitazone, and 
glimepiride individually or in combination with other drugs [19-35]. The 
aim of the study was to develop a reversed-phase liquid chromatography 
method and validate the same according to the ICH guidelines [18]. The 
possible degradation products of metformin, sitagliptin, pioglitazone, and 
glimepiride were generated by stress degradation, and the developed 
method was used successfully to separate and identify the degradation 
products from the analyte. This method can be applied for the determination 
of stability of the APIs during pre-formulation and formulation studies for 
the development of FDC in pharmaceutical laboratories.
MATERIALS AND METHODS
Instrumentation
Analytes were scanned between 200 and 400 nm using UV-visible 
spectrophotometer (Shimadzu, model UV-1700). Experiments were 
carried out using Shimadzu prominence Modular HPLC system with LC 
20AT solvent delivery unit, CBM 20A system controller, SIL 20A auto-
sampler, CTO 20A column oven, and SPD 20 A UV detector. Samples 
were injected at the flow rate of 1.0 mL/min. The pH of the solutions 
was measured with the pH meter (Mettler Toledo, S20K). Refluxing of 
the drugs in specific degradation conditions was carried out using a 
Rotavapor (R-300, Buchi). A Shimadzu ATX-124 analytical balance was 
used for weighing.
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Reagents and chemicals
The metformin, sitagliptin, pioglitazone, and glimepiride reference 
materials were purchased from Mesochem Technology Inc., Beijing, 
China. Methanol and water were used of HPLC grade and purchased 
from Fisher Scientific, India. Potassium dihydrogen phosphate buffer 
was purchased from Sigma-Aldrich Company, India.
Selection of wavelength
Standard solution of metformin, sitagliptin, pioglitazone, and 
glimepiride, 10 μg/mL each, was scanned between 200 and 400 nm 
using a UV-visible spectrophotometer. Wavelength was selected from 
the overlay spectra of the above solutions.
Chromatographic separation
Analytes were separated on Agilent XDB-C18, 150 mm × 4.6 mm, 
5 μm column using an isocratic elution mode having mobile phase 
composition of 20 mM potassium dihydrogen phosphate buffer 
(pH 4.0):acetonitrile (65:35% v/v). The detection was carried out at 
the wavelength of 225 nm. 20-μL fixed-loop was used for the injection 
of the samples with the flow rate of 1.0 mL/min.
Preparation of standard solutions
50 mg of metformin, 4 mg of sitagliptin, 2 mg of pioglitazone, and 
1.5 mg of glimepiride were separately weighed and dissolved in 
methanol to obtain 500 μg/mL of metformin, 40 μg/mL sitagliptin, 
20 μg/mL pioglitazone, and 15 μg/mL of glimepiride individual 
standard stock solutions. Working standard solution of mixture of 
metformin (50 μg/mL), sitagliptin (4 μg/mL), pioglitazone (2 μg/mL), 
and glimepiride (1.5 μg/mL) was prepared from the stock solution.
Method validation
System suitability test [18]
System suitability test is an integral part of the chromatographic 
method. These tests are used to verify that the resolution and 
reproducibility of the system are adequate for the analysis to be 
performed. System suitability tests are based on the concept that the 
equipment, electronics, analytical operations, and samples constitute 
an integral system that can be evaluated as a whole. System suitability 
testing provides assurance that the method will provide accurate and 
precise data for its intended use.
Linearity
The linearity was assessed by the analysis of combined standard 
solution in a range of 25–100 μg/ml for metformin, 2.5–10 μg/ml 
sitagliptin, 1–4 μg/ml pioglitazone, and 0.75–3 μg/ml glimepiride.
Precision
Results for inter-and intra-day precision were expressed as percentage 
relative standard deviation (%RSD) or coefficient of variance.
Repeatability
A standard solution containing 50 μg/ml of metformin, 5 μg/ml of 
sitagliptin, 2 μg/ml of pioglitazone, and1.5 μg/ml of glimepiride 
was injected 6 times, areas of peaks were measured, and %RSD was 
calculated to determine the repeatability of the method.
Intra- and inter-day precision
A standard solution containing 20, 50, and 75 µg/ml of metformin; 
2.5, 5, and 7.5 µg/ml of sitagliptin; 1, 2, and 3 μg/ml of pioglitazone, 
and 0.75, 1.5, and 2.25 µg/ml of glimepiride was analyzed 6 times on 
the same day for the determination of intraday precision and on 3 
different days for the determination of interday precision, and %RSD 
was calculated.
Accuracy
Accuracy was calculated at three different levels in terms of percentage 
recovery by spiking known amount of standard solution (80%, 
100%, and 120%) to the solution of a synthetic laboratory mixture of 
metformin, sitagliptin, pioglitazone, and glimepiride.
Specificity and selectivity
The specificity of the method was established through the study of 
resolution factors of the drug peak from the nearest resolving peak and 
also among all other peaks.
Limit of detection and limit of quantitation (LOD and LOQ)
The LOD and LOQ were estimated at signal-to-noise ratios of 3:1 and 
10:1, respectively, by injecting a series of dilute solutions with known 
concentrations.
Robustness
Robustness of the method was investigated by varying the 
chromatographic conditions, such as changing the flow rate by ±10%, 
i.e., 0.8 ml/min and 1.2 ml/min; changing the ratio of mobile phase 
was with ±2, i.e. 20 mM potassium dihydrogen phosphate buffer 
(pH 4.0):acetonitrile (63:37% v/v and 67:33% v/v); and changing 
the pH of the buffer in the mobile phase with ±0.2%, i.e., 3.7 and 3.3. 
Robustness of the developed method was indicated by the overall 
%RSD between the data, at each variable condition.
Analysis of synthetic laboratory mixture
Synthetic laboratory mixture of 50 mg of metformin, 4 mg of 
sitagliptin, 2 mg of pioglitazone, and 1.5 mg of glimepiride 
was weighed individually and spiked with 1 mg hydroxypropyl 
cellulose (E463) and 1 mg microcrystalline cellulose (E460(i)) as 
the excipients into a 100 ml volumetric flask. The analytes were 
extracted with 5 ml methanol by sonication in the ultrasonicator 
bath, and then, the solution was filtered through Whatman filter 
Paper No. 42. The final concentration of a mixture of 50 μg/ml 
of metformin, 5 μg/ml of sitagliptin, 2 μg/ml of pioglitazone, and 
1.5 μg/ml of glimepiride was made with mobile phase. Samples were 
analyzed using the developed assay. The areas of resulting peaks 
were measured at 225 nm.
Stress degradation studies
Acid hydrolysis
Forced degradation in acidic condition was performed by adding 
1 ml of standard solutions of metformin (500 μg/ml), sitagliptin 
(40 μg/ml), pioglitazone (20 μg/ml), and glimepiride (15 μg/ml) 
each individually to 6 ml methanol:water (1:1). To start the reaction, 
pH 3.0 was adjusted using 0.1 M hydrochloric acid. The mixture 
was incubated at 45°C for 2 h. The solution was then allowed to 
reach at room temperature, neutralized to pH 7.0 by the addition 
of 0.1 M sodium hydroxide, and diluted to 10 ml with the mobile 
phase so as to get a final concentration of 50 μg/ml for metformin, 
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4 μg/ml for sitagliptin, 2 μg/ml for pioglitazone, and 1.5 μg/ml for 
glimepiride.
Alkaline hydrolysis
Alkali-induced, forced degradation was performed by adding 
1 ml of standard solutions of metformin (500 μg/ml), sitagliptin 
(40 μg/ml), pioglitazone (20 μg/ml), and glimepiride (15 μg/ml) 
each, respectively, to 6 ml methanol:water (1:1). Adjusting the 
pH 12.0 using 0.1 M sodium hydroxide started alkali hydrolysis. The 
mixture was incubated at 45°C for 2 h (n=3). The solution was then 
allowed to reach at room temperature, neutralized to pH 7.0 by the 
addition of 0.1 M hydrochloric acid, and diluted to 10 ml with the 
mobile phase to get a final concentration of 50 μg/ml for metformin, 
4 μg/ml for sitagliptin, 2 μg/ml for pioglitazone, and 1.5 μg/ml for 
glimepiride.
Oxidative degradation
To evaluate the effect of oxidizing conditions, 1 ml of the standard 
solutions of metformin (500 μg/ml), sitagliptin (40 μg/ml), pioglitazone 
(20 μg/ml), and glimepiride (15 μg/ml) each separately was added to 
2 ml of 3% hydrogen peroxide solution, and the mixture was refluxed at 
45°C for 2 h. The solution was then allowed to reach room temperature 
and diluted to 10 ml with the mobile phase to get a final concentration 
of 50 μg/ml for metformin, 4 μg/ml for sitagliptin, 2 μg/ml for 
pioglitazone, and 1.5 μg/ml for glimepiride each individually.
Thermal degradation
To evaluate the effect of temperature, 1 ml of a standard solution 
of metformin (500 μg/ml), sitagliptin (40 μg/ml), pioglitazone 
(20 μg/ml), and glimepiride (15 μg/ml) was each incubated at 60°C 
for 2 h. The solutions were then allowed to reach room temperature 
and diluted to 10 ml with the mobile phase to get a final concentration 
of 50 μg/ml for metformin, 4 μg/ml for sitagliptin, 2 μg/ml for 
pioglitazone, and 1.5 μg/ml for glimepiride.
Photolytic degradation
To study the effect of UV light, 1 ml of each of the standard solutions of 
metformin (500 μg/ml), sitagliptin (40 μg/ml), pioglitazone (20 μg/ml), 
and glimepiride (1.5 μg/ml) was exposed to short and long wavelength 
UV light (254 nm and 366 nm, respectively) for 4 h. The volume was 
made up by the mobile phase to get final concentration equivalent to 
50 μg/ml of metformin, 4 μg/ml of sitagliptin, 2 μg/ml pioglitazone, and 
1.5 μg/ml of glimepiride.
Synthetic laboratory mixture was also treated with described acidic, 
alkaline, oxidative, thermal, and photolytic degradation conditions. 20 
μL of the resulting solutions were injected into the HPLC system, and 
the chromatograms were recorded.
RESULTS AND DISCUSSION
Method development
As metformin, sitagliptin, pioglitazone, and glimepiride showed 
absorbance response at a wavelength of 225 nm, it was selected as a 
wavelength of detection. Fig. 2 represents the overlay UV spectrum.
Analytes were separated on Agilent XDB-C18, 150 × 4.6 mm, 5μm column 
using an isocratic elution mode having mobile phase composition of 
20 mM potassium dihydrogen phosphate buffer (pH 4.0):acetonitrile 
(65:35% v/v). Analytes were detected at 225 nm. 20 μL fixed-loop 
injector was used for the injection of the samples with the flow rate of 
1.0 mL/min. Retention times were 3.47 min, 4.83, 5.83, and 9.44 min 
for metformin, sitagliptin, pioglitazone, and glimepiride, respectively, as 
shown in Fig. 3.
Fig. 2: Overlay ultraviolet spectrum of metformin, sitagliptin, 
pioglitazone, and glimepiride showing selection of wavelength 
detection
Fig. 3: Chromatogram of metformin (1), sitagliptin 
(2), pioglitazone (3), and glimepiride (4) in 20 mM potassium 
dihydrogen phosphate buffer (pH 4.0): acetonitrile (65:35 %v/v) 
with flow rate - 1.0 ml/min
Table 1: System suitability parameters for metformin, sitagliptin, pioglitazone, and glimepiride
System suitability parameters Metformin Sitagliptin Pioglitazone Glimepiride
Theoretical plates per column (N) 7657 4137 3672 2449
Symmetry factor/tailing factor 1.31 1.51 1.57 1.65
Resolution 4.97 2.63 7.32
Table 2: Results from regression analysis for metformin, sitagliptin, pioglitazone, and glimepiride
Description Metformin Sitagliptin Pioglitazone Glimepiride
Linearity and range 25–100 μg/ml 2–10 μg/ml 1–4 μg/ml 0.75–3 μg/ml
Regression coefficient 0.999 0.999 0.999 0.999
Slope (m) 93.23 264.67 330.61 2365.7
Intercept (c) −80.72 −33.91 −2.34 −85.41
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Method validation
The method was validated as per the ICH guidelines [17] with respect 
to parameters defining linearity, precision, accuracy, specificity, and 
robustness.
The number of theoretical plates, peak tailing, and resolution factor 
was determined to define system suitability parameters for metformin, 
sitagliptin, pioglitazone, and glimepiride. The results for system 
suitability data are listed in Table 1.
Linearity and range were assessed by the analysis of combined 
standard solution with the range of 25–100 μg/ml for metformin, 
2.5–10 μg/ml sitagliptin, 1–4 μg/ml pioglitazone, and 0.75–3 μg/ml 
glimepiride. Standard calibration curve for metformin, sitagliptin, 
pioglitazone, and glimepiride is represented in Figs. 4-7, respectively. 
The data for regression analysis are listed in Table 2. A standard 
solution containing 50 μg/ml of metformin, 4 μg/ml of sitagliptin, 
2 μg/ml of pioglitazone, and 1.5 μg/ml of glimepiride, respectively, 
was injected 6 times, and areas of peaks were measured to determine 
the repeatability of the method. %RSD. value for the determination of 
repeatability is represented in Table 3.
A standard solution containing 25, 50, and 75 µg/ml of metformin; 
2.5, 5, and 7.5 µg/ml of sitagliptin; 1, 2, and 3 µg/ml of pioglitazone; 
and 0.75, 1.5, and 2.25 µg/ml of glimepiride was analyzed 3 times 
on the same day for the determination of intraday precision and on 
3 different days for the determination of interday precision. %RSD 
values for intra- and inter-day precision are represented in Table 4. 
The accuracy of the method was confirmed by recovery study from 
the synthetic laboratory mixture at three levels of standard addition. 
The results are shown in Tables 5-8 for metformin, sitagliptin, 
pioglitazone, and glimepiride, respectively. Percentage recovery 
was in the range of 99.4–100.994% for metformin, 99.2–100.9 
sitagliptin, and 99.3–100.4% for glimepiride. LOD was 2.21 µg/ml, 
0.34 µg/ml, 0.10 µg/ml, and 0.12 µg/ml for metformin, sitagliptin, 
pioglitazone, and glimepiride, respectively, whereas LOQ was 
6.7 µg/ml, 1.04 µg/ml, 0.31 µg/ml, and 0.37 µg/ml for metformin, 
sitagliptin, pioglitazone, and glimepiride, respectively. The method 
was robust with %RSD values <2% with the deliberate changes in 
the composition of mobile phase, changes in the pH, or change in the 
flow rate. Applicability of the proposed method was evaluated by 
analyzing a synthetic laboratory mixture, and the results are shown 
in Table 9. The assay results were >99.0% for metformin, sitagliptin, 
pioglitazone, and glimepiride each, respectively, in synthetic 
laboratory mixture.
Establishment of stability indicating a method for the assessment 
of degradation behavior
The stressed samples were assayed using developed reversed-phase 
HPLC (RP-HPLC) method. Following degradation, behavior was 
observed under different stress conditions for the HPLC studies on the 
combination of metformin, sitagliptin, pioglitazone, and glimepiride 
(Tables 10-13).
Significant degradation was observed in the presence of acidic, basic, 
neutral oxidative, and photolytic stress conditions for metformin, 
sitagliptin, pioglitazone, and glimepiride, respectively (n=5). Percentage 
degradation for the standard drug was 14%, 13%, 12%, 13%, and 13% 
for metformin; 14%, 12%, 12%, 12%, and 13% sitagliptin; 17%, 27%, 
14%, 18%, and 19% for pioglitazone; and 18%, 20%, 12%, 18%, and 
18% for glimepiride in the presence of acidic, basic, thermal, oxidative, 
and photolytic degradation, respectively. Percentage degradation in 
synthetic laboratory mixture was 16%, 13%, 12%, 11%, and 15% for the 
metformin; 17%, 13%, 12%, 13%, and 14% for sitagliptin; 17%, 27%, 
19%, 17%, and 21% for pioglitazone; and 16%, 15%, 15%, 13%, and 
14% for glimepiride in the presence of acidic, basic, thermal, oxidative, 
and photolytic degradation, respectively. The percentage degradation 
was calculated by the formula: % Degradation=(Average peak area of 
untreated stock solution - average peak area of stock solution under 
specific degradation condition)/(average peak area of untreated stock 
solution) ×100).
Fig. 4: Standard calibration curve of metformin (25–100 μg/ml)
Fig. 5: Standard calibration curve of sitagliptin (2–10 μg/ml)
Fig. 6: Standard calibration curve of pioglitazone (1–4 μg/ml)
Fig. 7: Standard calibration curve of glimepiride (0.75–3 μg/ml)
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CONCLUSION
The overall demand for the development of FDC for antidiabetic 
drugs has been growing in the pharmaceutical market. This 
increases the need for the development of cost effective and high 
throughput assays. Proposed reversed-phase HPLC method was 
able to successfully separate and quantify metformin, sitagliptin, 
pioglitazone, and glimepiride simultaneously in the presence of their 





Amount of standard 
added (μg/ml)
Metformin
Amount recovered (μg/ml) % recovery % Mean recovery±SD
80% 25 20 20.24 101.21 100.70±0.93
25 20 19.93 99.62
25 20 20.26 101.29
100% 25 25 25.19 100.74 99.67±0.92
25 25 24.78 99.12
25 25 24.79 99.17
120% 25 30 29.57 98.57 98.84±0.66
25 30 29.88 99.60
25 30 29.51 98.36
SD: Standard deviation










% recovery % Mean recovery±SD
80% 2.5 2 2.02 101.21 100.06±1.15
2.5 2 2.00 100.07
2.5 2 1.98 98.91
100% 2.5 2.5 2.52 100.70 100.29±1.57
2.5 2.5 2.46 98.48
2.5 2.5 2.54 101.51
120% 2.5 3 2.99 99.81 99.24±0.95
2.5 3 2.94 98.14
2.5 3 2.99 99.78
SD: Standard deviation





Amount of standard 
added (μg/ml)
Pioglitazone
Amount recovered (μg/ml) % Recovery % Mean recovery±SD
80% 1 0.8 0.79 99.08 99.41±0.63
1 0.8 0.80 100.14
1 0.8 0.79 99.00
100% 1 1 1.01 100.81 101.14±0.42
1 1 1.01 101.01
1 1 1.02 101.61
120% 1 1.2 1.20 99.90 98.51±1.26
1 1.2 1.18 98.23
1 1.2 1.17 97.43
SD: Standard deviation





Amount of standard 
added (μg/ml)
Glimepiride
Amount recovered (μg/ml) % recovery % Mean recovery±SD
80% 0.75 0.6 0.60 100.26 99.82±0.69
0.75 0.6 0.60 100.17
0.75 0.6 0.59 99.02
100% 0.75 0.75 0.76 100.80 100.67±1.01
0.75 0.75 0.75 99.61
0.75 0.75 0.76 101.62
120% 0.75 0.9 0.90 99.90 98.51±1.2
0.75 0.9 0.88 98.22
0.75 0.9 0.88 97.41
SD: Standard deviation
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degradation products. This implies the stability indicating nature 
and specificity of the method. The developed validated stability 
indicating RP-HPLC method is simple, precise, accurate, robust, 
and reproducible resolving all the degradation products from the 
analytes of interest. The method validated as per the ICH guidelines 
and can be successfully used for the quantitative determination of 
metformin, sitagliptin, pioglitazone, and glimepiride and the stability 
of the analytes during the pre-formulation studies in pharmaceutical 
laboratories.
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1. Steinberg H, Anderson MS, Musliner T, Hanson ME, Engel SS. 
Management of dyslipidemia and hyperglycemia with a fixed-dose 
Table 9: Analysis of synthetic mixture by developed method
Synthetic laboratory mixture Analyte
Weight (mg) of synthetic laboratory 
mixture
Metformin (500 mg) Sitagliptin (50 mg) Pioglitazone (20mg) Glimepiride(15 mg)
Assay mean±SD (n=6) 99.61±0.45 99.24±0.97 99.53±0.69 100.82±0.93
SD: Standard deviation
Table 10: Percentage degradation of metformin with retention time of the degradation products
S. No. Conditions Retention time of metformin/
degradation products (min)
% Degradation of 
metformin (n=5)
% Degradation of metformin 
in synthetic mixture (n=5)
1 Untreated stock solution (10 μg/ml) 3.78 - -
2 Acid hydrolysis 4.51, 7.96 14.11 16.93
3 Alkali hydrolysis 2.53, 3.35, 5.12 13.63 13.02
4 Oxidative degradation 3.03, 5.35 12.36 12.09
5 Thermal degradation 2.64, 4.66 13.82 11.49
6 Photolytic degradation 2.44, 4.31 13.57 15.42
Table 11: Percentage degradation of sitagliptin with retention time of the degradation products
S. No. Conditions Retention time of sitagliptin/
degradation products (min)
% Degradation of 
sitagliptin (n=5)
% Degradation of sitagliptin in 
synthetic mixture (n=5)
1 Untreated stock solution (10μg/ml) 5.06 - -
2 Acid hydrolysis 4.12,7.29 14.31 17.08
3 Alkali hydrolysis 2.83, 5.00 12.22 13.08
4 Oxidative degradation 2.90, 5.14 12.73 12.39
5 Thermal degradation 2.90, 5.12 12.55 13.59
6 Photolytic degradation 2.82, 4.97 13.86 14.03
Table 12: Percentage degradation of pioglitazone with retention time of the degradation products
S. No. Conditions Retention time of pioglitazone/
degradation products (min)
% Degradation of 
simvastatin (n=5)
% Degradation of pioglitazone in 
synthetic mixture (n=5)
1 Untreated stock solution (10 μg/ml) 8.57 - -
2 Acid hydrolysis 4.85, 7.01 17.35 17.75
3 Alkali hydrolysis 4.86, 7.54 27.45 27.38
4 Oxidative degradation 4.87, 8.52 14.27 19.65
5 Thermal degradation 4.33, 4.84 18.30 21.77
6 Photolytic degradation 4.84, 5.41 19.56 19.17
Table 13: Percentage degradation of glimepiride with retention time of the degradation products
S. No. Conditions Retention time of glimepiride/
degradation products (min)
% Degradation of 
simvastatin (n=5)
% Degradation of glimepiride in 
synthetic mixture (n=5)
1 Untreated stock solution (10 μg/ml) 8.57 - -
2 Acid hydrolysis 10.43 15.27 15.92
3 Alkali hydrolysis 7.64 15.60 15.52
4 Oxidative degradation 9.64, 11,66 12.50 15.54
5 Thermal degradation 10.43, 11.66 18.43 18.40
6 Photolytic degradation 9.99 18.92 19.07
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